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This study was designed to evaluate the effects of puri ied monosodium glutamate and ‘Maggi Poulet’, 
on body weight gain, lipid profile, hepatic lipid peroxidation and glucose tolerance in rats. Thirty five young 
male Sprague Dawley rats were divided into five groups and fed by oral route as follow: group I (distilled 
water), group II (monosodium glutamate solution), group III (‘Maggi Poulet’solution), group IV (monosodium 
glutamate solution. and high fat solution) and group V (‘Maggi Poulet’ solution and high fat solution). During 
the experimental period, fasting glycemia was taken and an oral glucose tolerance test has been performed at 
the end . Blood samples were then collected in all groups and serum cholesterol and triglyceride were assayed. 
Animals were killed after and abdominal adipose tissue, liver and heart were excised and weighed. Liver 
samples were also used to estimate hepatic malondiadehyde level in rats. The results proved that the dietary 
feeding did not affect the body gain and lipid profile in experimental groups. The hepatic lipid peroxidation has 
also increased in all experimental groups and at the same time, rats in group II, group IV and group V resent a 
two-hour plasma glucose level signifantly higher. However, purified monosodium glutamate and ‘Maggi 
Poulet’ at the dose of 1500 mg/kg. b. wt. have not impaired fasting glycemia in Sprague Dawley rat. All 
changes observed in the glycemia of rats in experimental groups do not allow to qualify them to be glucose 
intolerant, nevertheless monosodium glutamate consumption in association or not with high fat is hepatotoxic 
and may contribute to the emergence of prediabetes in human being. 
© 2013 International Formulae Group. All rights reserved. 




Impaired glucose tolerance (IGT) and 
impaired fasting glucose (IFG) are 
intermediate states of abnormal glucose 
regulation that exist between normal glucose 
homeostasis and diabetes (David et al., 2007). 
These two features of glucose intolerance 
differ in their site of insulin resistance. IFG is 
associated with hepatic insulin resistance 
whereas IGT manifest itself by muscle insulin 
resistance (Brohall et al., 2006). According to 
the recommendations of the American 
Diabetes Association; IFG is defined for 
fasting plasma glucose level in the range of 
100 to 125 mg/dl and a two-hour plasma 
glucose level less than 140 mg/dl and IGT is 
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characterised by a fasting plasma glucose less 
100 mg/dl , a two-hour plasma glucose level 
going from 140 to 199 mg /dl and the glycated 
haemoglobin A1c rate included between 5.7% 
to 6.4% (Buysschaert and Bergam, 2011). 
It is generally agreed that genetic 
background, dietary habits and physical 
inactivity may contribute to the pathogenesis 
of these disorders. In order to improve the 
understanding of the mechanisms involved in 
the onset of insulin resistance and obesity; 
various rodent models have been developped. 
Based upon genetic susceptibility, there are 
close to 50 different types of genetic models 
of obesity in rodents among which, obese 
mice (ob/ob, db/db) and Zucker rats (fa/fa) are 
used as sample animals of diabetes in 
biological and medical studies (Von Diemen 
et al., 2006). There are also diabetic rodent 
models obtained through chemical induction 
using gold-thioglucose, alloxan or 
streptozocin (Huang et al., 2004) and 
experimental ablation of the pancreas or the 
arcuate nucleus (Von Diemen et al., 2006).  
However, those previous models do not 
sufficiently manifest prediabetic state when 
we need to extrapolate results from rodent to 
human being. Dietary rodent models are 
therefore proposed and several substances 
such as high fat, trans-fat, sucrose, fructose 
and recently monosodium glutamate (MSG) 
have been proposed (Diniz et al., 2004; 
Collison et al., 2010, Singh et al., 2011). In 
most cases, MSG subcutaneous injections or 
large oral dose of MSG dietary 
supplementation in rodent have shown an 
impairment of glucose homeostasis, a 
dyslipidemia and weight gain (Hermanussen 
et al., 2006).  
In contrast to previous studies, Boutry 
et al. (2011) have reported that 2% MSG diet 
chronic supplementation had no effect on food 
intake, body weight, and adipose tissue mass 
in Wistar rat. Furthermore, Kondoh and Torii 
(2008) reported that 1% MSG dissolved in the 
drinking water was able to reduce weight 
gain, body fat mass, and plasma leptin 
concentrations in Sprague Dawley rats. The 
mechanism underlying MSG-induced obesity 
and insulin resistance in non physiological 
situation remains unclear and controversial 
(Boutry et al., 2011). 
The use of bouillon cube containing 
MSG in spite of purified MSG in household 
preparation of food is very popular in Sub-
Saharan African countries (Sop et al., 2008; 
Akpamu et al., 2011). ‘Maggi Poulet’ (MP) is 
one of the most commonly cube-type 
seasoning added to soups in Lomé (Togo). 
Sop et al. (2008) have estimated the average 
free MSG content of MP to 13.5% (wt./wt.). 
The aim of this study is to investigate the 
effect of dietary MSG and MP with or without 
high fat supplementation on weight gain, lipid 
profile, hepatic lipid peroxidation and glucose 
tolerance in Sprague Dawley rat. 
 
MATERIALS AND METHODS 
Chemicals 
Lard, MSG (West African Seasoning 
Company Limited, Lagos Nigeria) and MP 
(Nestlé Company, Dakar Senegal) were 
purchased from ‘Gbonsimé’ market, Lomé 
(Togo). Other chemicals such as thiobarbituric 
acid, phosphoric acid and cholesterol were 
from Sigma-Aldarich, France. Elitech/Biolabo 
kits, France, were used for estimation of total 
cholesterol, HDL cholesterol and 
triglycerides.   
 
Animals  
Male Sprague Dawley (n=35) strain 
weighing about 160 g were used for the 
experiments. The animals were provided by 
Nogoshi Medical Institute (University of 
Legon, Ghana). They were kept on a 12:12-h 
light–darkness cycle at the Animal House of 
the University of Lomé (Togo). They had free 
access to the standard diet and water ad 
libitum. All animals were acclimated for 2 








The rats were divided into five groups 
of seven animals each and treated as follow: 
-Group I (control): the rats received distilled 
water (5 ml/kg b. wt.) and thirty minutes after 
another dose of 10 ml/ kg b. wt of the same 
distilled water 
-Group II (MSG): the rats received 
monosodium glutamate aqueous solution 
(1500 mg/kg b. wt.) and thirty minutes after 
another dose of 10 ml/kg b. wt of the distilled 
water 
-Group III (MP): the rats received ‘Maggi 
Poulet’ aqueous solution (1500 mg/kg b. wt.) 
and thirty minutes after another dose of 10 
ml/kg b. wt. of the distilled water 
-Group IV (MSG-HF): the rats received 
monosodium glutamate aqueous solution 
(1500 mg/kg b. wt.) and thirty minutes after 
another dose of 10 ml/kg b. wt. of high fat 
solution  
-Group V (MP-HF): the rats received ‘Maggi 
Poulet’ aqueous solution (1500 mg/kg b. wt.) 
and thirty minutes after another dose of 10 
ml/kg b. wt. of high fat solution.  
Hight fat solution was prepared by 
dissolving 400 mg of cholesterol in 10 ml of 
melted lard. The total treatment period was 
sixty days and substance administration daily 
lasted one hour (9:00 a. m-10:00 a. m).  
During the experimentation animals’ 
body weight were measured daily while 
fasting glycemia was taken the first day and 
two weeks later using One Touch Ultra 2 
glucometer. At the end of the treatment (60 
days), all the rats were fasted overnight (12-14 
h) for the oral glucose test tolerance (OGTT). 
Eighty per cent glucose aqueous solution was 
orally administered by gastric tube at the dose 
of 4 g/kg b. wt per rat. Blood glucose rates 
were measured at tail vein before glucose 
administration and at 30, 60, 120 min after the 
glucose administration. After the OGTT, 
blood samples were collected with a capillary 
tube from retro-orbital plexus of rat under 
ether anaesthesia. The collected blood was 
incubated at 37 ºC until clotted and then, it 
was centrifuged to separate the serum. The 
serum samples were frozen to be used for 
measurement of total cholesterol (TC), HDL 
cholesterol (HDL-chol) and triglyceride (TG). 
Animals were killed by cervical decapitation 
and the abdominal cavity was opened. Liver, 
heart and intra-abdominal adipose tissue were 
dissected and weighed. Liver samples were 
frozen during 48 hours and hepatic lipid 
peroxidation was estimated by quantification 
of malondialdhehyde thiobarbituric acid 
adduct (MDA-TBA). Briefly, liver samples 
(150 mg) were homogenised with cold 1.5% 
KCl in order to make 10% homogenate. Three 
millimetres of phosphoric acid and 1 ml of 
0.6% thiobarbituric acid aqueous solution 
were added to 0.5 ml of the homogenate. The 
mixture was heated for 45 min. After cooling, 
4 ml of n-butanol was added to the 
homogenate and mixed. Absorbance of 
butanol phase was measured at 535 and 520 
nm. The difference of the two measurements 
was used as MDA concentration expressed in 
nmol/g tissue (Sepici-Dincel et al., 2007; 
Bakoma et al., 2011) 
 
Data analysis 
All results were analysed using Graph 
Pad Prism 4.5 and expressed as mean ± 
S.E.M. The significance of the difference 
between each group was determined by one 
way analysis of variance followed by Turkey 
post-hoc test (p<0.05).  
 
RESULTS  
As shown in Table 1, the final body 
weight, the body weight gain and the relative 
heart weight did not differ into the groups. 
Relative intra-abdominal fat deposition 
(mesenteric, retroperitoneal and epididymal 
fat) and relative liver weight were markedly 
higher in MSG-HF and MP-HF treated groups 
compared to the control group.  
Overnight fasting glucose was not 
influenced neither by controlled diet nor MSG 
and MP ingestion. However, mean fasting 
glucose in MSG-HF and MP-HF groups had 
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significantly increased from 15th day onward 
till the end of the experimental period (Table 
2). The OGTT showed that there were no 
differences in glucose rate after loading in 
controlled and MP groups. Otherwise, the 
glucose level after loading in MSG-HF group 
peaked and was the highest among all groups 
during the test (Table 3). At 120 min post-
glucose challenge, glucose concentrations 
were significantly higher in MSG, MSG-HF 
and MP-HF rats groups compared to the 
control (p<0.05). All rats in experimental 
groups tended to have elevated glucose area 
under curve (AUC) during the OGTT 
compared to the control; nevertheless only 
MSG-HF rats presented a glucose AUC 
significantly higher (+23% versus control 
group). 
In addition, there were no differences 
in total cholesterol, HDL cholesterol, LDL 
cholesterol, triglyceride into the five groups 
after dietary feeding (Table 4). Liver tissue 
MDA levels in contrast were significantly 
increased in all experimental groups compared 




Table 1: Effect of diets on body weight, and relative tissue weight after 60 days supplementation. 
 
Groups Parameters 
Control MSG MP MSG-HF MP-HF 
Initial body weight (g) 171.8±3.16 169.71±2.86 169.57±4.79 170.66±3.6 169±3.17 
Body weight gain (g) 102.4±5.65 128.71±7.66 101.57±2.82 105.50±3.36 102±7.67 
Final body weight (g) 274.2±8.83 289.42±10.54 271.14±7.62 275.16±6.96 271±5.83 
Relative liver weight (g) 2.42±0.08 2.53±0.08 2.54±0.07 2.85±0.04a 2.7±0.06a,c 
Relative heart weight (g) 0.33±0.01 0.35±0.02 0.40±0. 1 0.36±0.01 0.40±0.01 
Relative intra-abdominal 
adipose tissue weight (g) 
1.54±0.09 1.83±0.17 1.50±0.14 2.04±0.06 a,b 2.58±0.17a,c 
Each value is expressed as mean ± standard error mean for seven rats per dietary group. The data were evaluated by ANOVA 
followed by Turkey post-hoc test at 5%. Relative liver weight was expressed as g liver x 100/ g body weight. Relative intra-
abdominal adipose tissue weight was expressed as g intra-abdominal adipose tissue weight x100/ g body weight. ( a 





Table 2: Effect of diets on fasting glycemia during experimentation. 
 
Blood glucose levels (mg/dl)  
Groups 1st day 15th day 30th day 45th day 60th day 
Control 67.40±0.97 60.40±1.24 65.20±2.97 63.00±1.00 64.20±2.20 
MSG 71.14±1.76 67.1±2.00 68.00±2.32 66.57±2.18 67.00±1.5 
MP 69.28±1.68 64.85±1.53 63.42±2.33 64.42±2.42 65.00±1.48 
MSG-HF 69.00±1.75 79.40±0.60a,b 76.40±1.80 a,b 75.66±2.87 a,b 80.16±2.8a,b 
MP-HF 72.14±1.98 72.85±2.26a,c 76.40±1.88a,c 78.00±2.6a,c 78.28±1.4a,c 
Blood glucose concentration was taken from consciou fasting rat at tail vein. Each value is expressed as mean ± 
standard error mean for seven rats per dietary group. The data were evaluated by ANOVA followed by Turkey post-hoc 
test at 5%. a Significantly different from control group, b significantly different from MSG group, c significantly different 
from MP group. 
 
 






Table 3: Blood glucose rates after 60 days treatment on fasting conditions and 30, 60, 120 min after 
oral glucose intake. 
 
Groups  
Parameters Control MSG MP MSG-HF MP-HF 
Fasting glycemia  
(mg/dl) 
66.20±1.93 67.28±1.52 65.00±1.48 80.14±2.43a, b 79.00±1.21a, c 
Glycemia 30 min  
after glucose intake 
(mg/dl) 
113.00±6.39 117.42±3.81 107.57±2.14 135.85±7.97a 120.85±1.54 
Glycemia 60 min  
after glucose intake 
(mg/dl) 
111.80±6.32 112.57±5.91 120.57±4.70 134.16±4.49 a, b 107.00±1.55 
Glycemia 120 min  
after glucose intake 
(mg/dl) 
70.00±3.54 93.71±3.86a 83.85±4.61 99.85±3.35 a 94.28±5.87a 
Area under curve 
   (mg x min/ dl) 
11514±370.6 12409.2±418.1 12143.5±334.8 14185.7±488.6a 12454.2±228.7 
Eighty per cent glucose solution was directly introduced by gavage into the stomach of fasted  rat at  dose of 4g/ kg b. wt. 
Blood glucose concentration was taken on conscious rat at tail vein using One Touch Ultra Two Glucometer before, 30, 60, 
120 min after glucose load. Each value is expressed a  mean ± standard error mean for seven rats per dieta y group. The data 
were evaluated by ANOVA followed by Turkey post-hoc test at 5%. a Significantly different from controlled group, b 





Table 4: Effect of diets on lipid profile and hepatic oxidative stress after 60 days supplementation. 
 
Groups  
Parameters Control MSG MP MSG-HF MP-HF 
Total cholesterol (g/l) 0.67±0.06 0.68±0.06 0.67±0.02 0.63±0.03 0.75±0.05 
Triglycerides (g/l) 0.44±0.02 0.45±0.04 0.42±0.02 0.43±0.02 0.52±0.02 
 HDL cholesterol (g/l) 0.46±0.02 0.41±0.05 0.51±0.03 0.47±0.03 0.52±0.02 
LDL cholesterol (g/l) 0.11±0,05 0.18±0.06 0.19±0.13 0.02±0.02 0.17±0.03 
Malondialdehyde 
(nmol/mg tissue)  
1.40±0.27 2.98±0.52a 2.62±0.16 a 2.97±0.08 a 2.88±0.12 a 
 
Total cholesterol, triglycerides and HDL cholesterol were assayed by enzymatic colorimetric method using Elitech/Biolabo 
kits. LDL cholesterol was estimated by Friedewal et al. (1972) empirical equation. Malondialdehyde concentration was 
estimated by thiobarbituric acid method (Bakoma et l., 2011). Each value is expressed as mean ± standard error mean for 
seven rats per dietary group. The data were evaluated by ANOVA followed by Turkey post-hoc test at 5%. a Significantly 
different from controlled group. 
 
 




Monosodium glutamate is a worldwide 
used flavour enhancer with a level of 
consumption that has increased during the last 
two decades (Insawang et al., 2012). It can be 
used as purified glutamate salt or as a 
component of a mixture of amino acids and 
small peptides commonly called bouillon 
cube. This study was performed to analyse the 
effects of oral dose of purified MSG and MP 
(a bouillon cube containing 13% of MSG) 
supplementation in combination or not with 
high fat on weight gain, body fat, lipid profile, 
glycemia and hepatic lipid peroxidation in 
Sprague Dawley rat. From our viewpoint, this 
is the first study that analyses systemic and 
morphological effects of MP compared to 
purified MSG ingestion in rat. We tested in 
sub-chronic conditions (60 days) a supra-
nutritional dose of 1500 mg of MSG or MP 
per kilogramme body weight in growing 
Sprague Dawley rat. 
As expected, MSG or MP sub-chronic 
supplementation had no effect on body 
weight, gain, liver weight, heart weight and 
abdominal fat deposition. Our results are in 
accordance with those of Tordoff et al. (2012) 
who reported that 3% MSG in diet or in 
drinking water did not influence body weight 
and body fat store in three different species of 
rodents (Sprague Dawley rat, Obesity-prone 
Sprague Dawley derivated rat and C57BL\6J 
mouse) These findings are also in line with 
previous data from Boutry et al. (2011) who 
used a similar dose of 1295 mg MSG/ kg b. wt 
in diet or drinking water of Wistar rat. 
However, it has been suggested in several 
animal studies that MSG is able to induce 
overweight or obesity. In these MSG-induced 
obesity rat models; MSG is injected 
subcutaneously to newborn rats or 
administered by oral route at higher doses 
(5000 mg MSG/day) to young rats 
(Hermanussen et al., 2006). The induction of 
obesity in animals treated in this manner 
required that plasma GLU concentrations be 
elevated to very high values, sufficient enough 
to penetrate into the brain and exert 
deleterious effects on the arcuate nucleus 
neurons. Plasma hyperglutamataemia thereby, 
can disrupt the hypothalamic signaling 
cascade of leptin action and cause 
hyperphagia and obesity (Diniz et al., 2005; 
Kondoh and Torii 2008; Boutry et al., 2011). 
In our conditions, since rats did not manifest 
deleterious effects of overweight and obesity; 
it seems therefore that GLU derived from MP 
or MSG ingested is almost entirely (up to 
95%) catabolised by the enterocyte of 
intestinal mucosa (Beyreuther et al., 2007). 
The combination of MSG and high fat 
or MP and high fat feeding resulted in an 
increase of relative liver weight and 
abdominal fat deposition. This result is not 
unexpected as far as lard-based diets induced 
hepatic steatosis and are recommended as one 
of the standard fats to be used for the 
generation of a valid rat model for the 
metabolic changes associated with obesity 
(Buettner et al., 2006) 
The present work demonstrates that 
both MSG and MP sub-chronic ingestion in 
Sprague Dawley rat did not increase fasting 
glycemia during the supplementation. 
However, the oral glucose challenge 
generated a normal blood glucose response in 
MP rats whereas a hyperglycemic response 
was observed in MSG rats. In this way, MP 
fed rats’ plasma glucose concentration 
declines to near baseline values at 120 min 
after load while it remained significantly 
higher in MSG fed Sprague Dawley rat. These 
results highlight the reduction of glucose 
utilisation by peripheral tissues in postprandial 
conditions in MSG fed rats. Elevated plasma 
glutamate is well known to enhance insulin 
secretion which can lead to hyperinsulinemia 
and insulin resistance in sub-chronic 
conditions (Chevassus et al., 2002). The low 
amount of MSG contained in the MP diet may 
explain the relative normal glucose 
homeostasis observed in this group. In MSG-
HF and MP-HF diet groups; lard has 
exacerbated glucose intolerance by increasing 
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fasting glucose levels and glucose AUC 
during the OGTT. Huang et al. (2004) pointed 
out in their report that prolonged high fat diet 
supplementation can cause abnormality of the 
pancreas function and impaired insulin 
secretion. However, the alteration of glucose 
homeostasis in all experimental rats is not 
elevated to such point to be considered as 
prediabetic animals while basing esclusively 
on glucose criteria (Buysschaert and Bergam, 
2011). 
Serum lipids were all within the normal 
range and did not differ into the five groups 
whereas hepatic lipid peroxidation (MDA) 
had increased in all experimental groups. Such 
findings indicate that MSG and MP oral 
ingestion do not cause dyslipidemia but 
induce oxidative stress in Sprague Dawley rat. 
Kondoh and Torii (2008) also observed that 
the voluntary ingestion of 1% MSG solution 
had no effect on lipid profile in Sprague 
Dawley rat. However, lipid profile in MSG 
fed rats is very different from data obtained by 
Singh et al. (2011) who reported that the oral 
ingestion of MSG at dose level of 4 and 8 mg/ 
b. wt. signifanctly increased the level of serum 
lipid by 19.93% and 29.37%  in male Wistar 
rat during 7 days supplementation. They 
suggest that glutamate favours lipogenesis by 
converting to glutamine. This hypothesis is 
confirmed by Boutry et al. (2011), who 
demonstrated that after 15 days of 2% MSG 
dietary adaptation in Wistar rat, the circulating 
glutamine concentration has increased. We 
suggest therefore that Wistar rat could be 
more sensitive to the effects of MSG than 
Sprague Dawley rat. On the other hand, 
Egbuonu et al. (2009) found that oral intake of 
low dose of MSG (5 mg/b. wt.) by gastric tube 
in Wistar rat may be destructive to the liver. 
The mechanism involved in the production of 
hepatic MDA may be the generation of 
reactive oxygen species by MSG which is also 
an endogenous excitotoxin (Ortiz et al., 2006; 




To sum up, this study shows that sub-
chronic MP or MSG administration (60 days) 
at a dose of 1500 mg/b.wt. does not impair 
glucose tolerance but it promotes hepatic lipid 
peroxidation in male Sprague Dawley rat. A 
combination of MSG and high fat or MP and 
high fat supplementation in Sprague Dawley 
rat during growth may predispose to a glucose 
homeostasis impairment. The findings of this 
work are supplemental data confirming earlier 
reports on the hepatotoxicity and the potential 
role of MSG in the increasing prevalence of 
prediabetes and metabolic syndrome in human 
being. Further investigations using long term 
supplementation of MSG at various doses in 
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